P. Meden et al., THE INFLUENCE OF BODY-TEMPERATURE ON INFARCT VOLUME AND THROMBOLYTIC THERAPY IN A RAT EMBOLIC STROKE MODEL, Brain research, 647(1), 1994, pp. 131-138
The effect of body temperature on cerebral infarcts and thrombolytic t
herapy was investigated in 91 rats embolized in the right carotid terr
itory. Hypothermia of 32 degrees C for 2 h with preembolic onset (n =
15) or hyperthermia of 39 degrees C for 2 h with postembolic onset (n
= 22) was compared to normothermic controls (n = 17). After 48 h of su
rvival, neuropathological evaluation with measurement of infarct volum
e was performed. Median infarct volume in percent of affected hemisphe
re volume was 11% (9-21, quartiles) in rats treated with hypothermia a
lone, compared to 46% (14-59, quartiles) in normothermic controls (P =
0.04). Hyperthermia for 2 h increased median infarct volume to 65% (3
7-75, quartiles). There was a positive and significant correlation bet
ween infarct volume and body temperature (R = 0.53, P = 0:0002, n = 54
). Mortality rate was significantly higher among rats treated with hyp
erthermia compared to normothermic controls (P = 0.005). A subset of 3
7 rats exposed to the same temperature regimen were treated with tissu
e plasminogen activator (20 mg/kg i.v. during 45 min)2 h after emboliz
ation. Judged by posttreatment carotid angiography, hyperthermic rats
(n = 11) had the best degree of recanalization (P = 0.03) compared to
controls (n = 17), but median infarct volume in this group was (58% (2
7-67, quartiles)) significantly larger (P < 0.02) than normothermic (2
1% (15-39, quartiles), n = 14) and hypothermic (13% (7-31, quartiles),
n = 12) rats treated with thrombolytic therapy. Thrombolytic therapy
following 2 h of hypothermia, could not improve the effect of hypother
mia alone. We conclude, that the size of infarcts in our embolic strok
e model is dependent on the body temperature during the initial phase
of infarct development. Hyperthermia had a detrimental effect when com
bined with thrombolytic therapy and should be avoided in clinical tria
ls of this treatment.